ArticleScience translational medicine2019
IFN-γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus.
Article in Science translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06158113 (Efficacy and Safety of Baricitinib for the Treatment of Oral Lichen Planus), which is not on this map. Cited by 96 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Baricitinib for the Treatment of Oral Lichen Planus: A Proof-of-Concept Study
Who cites it
96 citing papers in PubMed, 6 syntheses or guidelines pooled it, 167 citations in OpenAlex.
- Janus kinase inhibitors in the management of lichen planus: a systematic review.Annals of medicine · 2026Pooled it
- Off-Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives.Experimental dermatology · 2025Pooled it
- Off-label use of JAK1 inhibitor upadacitinib in dermatology.Archives of dermatological research · 2025Pooled it
- Keratinocytes as active regulators of cutaneous and mucosal immunity: a systematic review across inflammatory epithelial disorders.Frontiers in immunology · 2025Pooled it
- γδ T cells in oral diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Pooled it
- The Use of Janus Kinase Inhibitors for Lichen Planus: An Evidence-Based Review.Journal of cutaneous medicine and surgeryPooled it
- Rapid response of lichen planus to baricitinib associated with suppression of cytotoxic CXCL13+CD8+ T cells.The Journal of clinical investigation · 2024Trial
- [Treatment-refractory lichen ruber exanthematicus].Dermatologie (Heidelberg, Germany) · 2026Article
- Efficacy and Safety of Ruxolitinib Cream in Patients With Cutaneous Lichen Planus: A Randomized Clinical Trial.JAMA dermatology · 2026Article
- The role of inflammatory cell death in type 1 dominant inflammatory skin diseases.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Review
- Refractory nail lichen planus treated successfully with the Janus kinase 1 inhibitor abrocitinib: A case report.The Journal of international medical research · 2026Article
- Dupilumab as a novel therapy for eruptive lichen planus in an Asian patient with metabolic syndrome.Skin health and disease · 2026Article
- Refractory oral and cutaneous lichen planus successfully treated with upadacitinib.JAAD case reports · 2026Article
- Cutaneous and erosive oral lichen planus treated with upadacitinib.JAAD case reports · 2026Article
- Signal Transduction and Transcription Activator 1 in Pan-Cancer: Prognostic and Immunological Value.Clinical and experimental medicine · 2026Article
- Single-cell and spatial profiling reveal cDC2A-CXCL13Nature communications · 2026Article
- Selective JAK Inhibition Reveals Paradoxical and Hierarchical Control of interferon-γ-driven Autoimmunity in AIRE Deficiency.bioRxiv : the preprint server for biology · 2026Article
- Spatial and Single-Cell Transcriptomics Reveal Keratinocytes as Key Players in Vulvar Lichen Sclerosus Pathogenesis.The Journal of investigative dermatology · 2026Article
- Dermatology 2.0: Precision medicine for inflammatory skin diseases.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Review
- Inflammatory niches as spatial drivers of disease mechanisms and targets for personalized treatment.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Review
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 4 institutions in 2 countries.
Funding
Abstract
Lichen planus (LP) is a chronic debilitating inflammatory disease of unknown etiology affecting the skin, nails, and mucosa with no current FDA-approved treatments. It is histologically characterized by dense infiltration of T cells and epidermal keratinocyte apoptosis. Using global transcriptomic profiling of patient skin samples, we demonstrate that LP is characterized by a type II interferon (IFN) inflammatory response. The type II IFN, IFN-γ, is demonstrated to prime keratinocytes and increase their susceptibility to CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.